

HEPATOBIILIARY DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
ROOM: ROSSETTI

SATURDAY APRIL 29TH, 2023 02:30 PM – 03:30 PM

CO-CHAIRS : DR. PAUL KARANICOLAS & DR. VINCENT TAM
SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical and translational research, the disease burden associated with hepatobiliary malignancies in Canada.
- To identify clinical trial research opportunities in hepatobiliary malignancies within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to hepatobiliary malignancies.
- To integrate and apply new clinical trial methodologies in hepatobiliary malignancies in the Canadian Cancer Trials Group research agenda
- To provide a learning and mentoring environment supportive to new investigators.

| | | |
|----------------|--|------------------------------------|
| 2:30 pm | Welcome | |
| 2:30 pm | Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) - Concept | Dr. J. Knox Dr. E. Sanz |
| 2:40 pm | Canadian Cholangiocarcinoma Collaborative (C3) | Dr. R. Auer |
| 2:50 pm | Future directions and research opportunities for radiotherapy in HCC and liver mets | Dr. L. Dawson |
| 3:20 pm | NCTN Hepatobiliary Taskforce Update | Dr. V. Tam |
| 3:30 pm | Meeting Adjourned | |

